Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Painengda is a Traditional Chinese Medicine (TCM) capsule developed by the Zhejiang Provincial Hospital of Traditional Chinese Medicine for the treatment of immune thrombocytopenia (ITP). It is specifically formulated for patients presenting with Qi and Blood deficiency syndrome, a common TCM diagnostic pattern. The drug is currently being evaluated in Phase II clinical trials (e.g., CTR20140835) to determine its efficacy and safety in increasing platelet counts and reducing bleeding symptoms. As a multi-component herbal preparation, its mechanism of action likely involves immunomodulation and the promotion of megakaryocyte maturation and platelet release, although specific molecular targets have not been definitively characterized in clinical literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Painengda (Zhejiang Provincial Hospital of Traditional Chinese Medicine).